Zeroing in on amyloid proteins in Alzheimer disease therapy.
The authors have provided us with a complete review of the approaches to the amyloid proteins of Alzheimer's disease in regards to targets for drug therapy. Sufficient information is now available concerning systemic amyloidogenesis, genes for familial Alzheimer's disease and the beta amyloid precursor protein, as well as the posttranslational processing requirements for amyloidogenesis and its prevention. Recent excitement concerning the roles for serine proteases and their inhibitors, both in the production and prevention of amyloidogenesis, make this review and its publication in the Neurobiology of Aging extremely timely.
Festoff
B W
BW
Kansas City Veterans Administration Medical Center, MO 64128.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D000682:Amyloid / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor; D005786:Gene Expression Regulation; D006801:Humans; D011498:Protein Precursors / Q000378:metabolism*; D012697:Serine Endopeptidases / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*
D000682:Amyloid; D016564:Amyloid beta-Protein Precursor; D011498:Protein Precursors; D015842:Serine Proteinase Inhibitors; D012697:Serine Endopeptidases